BioAge Labs Halts Phase 2 Obesity Trial Due to Liver Safety Concerns Just Two Months After IPO

Trial Discontinuation:
BioAge Labs has discontinued its Phase 2 STRIDES study of azelaprag, an investigational drug candidate for obesity, due to liver safety concerns13.

Liver Enzyme Elevations:
11 subjects in the azelaprag treatment groups showed transaminase (liver enzyme) elevations without clinically significant symptoms13.

Collaboration:
The study was conducted in collaboration with Eli Lilly And Co's Chorus clinical development organization13.

Recent IPO:
The halt comes just two months after BioAge Labs' initial public offering (IPO), which raised approximately $238.3 million25.

Future Plans:
BioAge Labs will further analyze the available clinical data and share updated plans for azelaprag in the first quarter of 202513.

Financial Status:
As of September 30, BioAge had approximately $334.5 million in cash and cash equivalents, expected to be sufficient to fund operations into 202913.

Sources:

1. https://www.benzinga.com/general/biotech/24/12/42387175/just-two-months-after-ipo-bioage-labs-stops-eli-lilly-collaborated-obesity-trial-on-safety-concerns

2. https://ir.bioagelabs.com/news-releases/news-release-details/bioage-labs-announces-pricing-upsized-initial-public-offering

3. https://www.aol.com/just-two-months-ipo-bioage-144122545.html

5. https://www.stocktitan.net/news/BIOA/bio-age-labs-announces-closing-of-initial-public-offering-full-yhcwn8aa9hxl.html